Table of Contents Table of Contents
Previous Page  22 / 24 Next Page
Information
Show Menu
Previous Page 22 / 24 Next Page
Page Background

Randomized Phase II or first line phase III studies

FOLFIRINOX

PEGPH20

Gemcitabine + Nab-paclitaxel

PEGPH20

Ibrutinib

MM-141

BBI-608

US: 54 Phase 1-3 trials for metastatic disease, only 2 incorpórate

FOLFIRINOX.

M. Tempero, presented in WGI 2016